Effectiveness of azithromycin mass drug administration on trachoma: a systematic review

Azithromycin mass drug administration (MDA) is a key part of the strategy for controlling trachoma. This systematic review aimed to comprehensively summarize the present studies of azithromycin MDA on trachoma; provide an overview of the impact of azithromycin MDA on trachoma in different districts;...

Full description

Saved in:
Bibliographic Details
Published in:Chinese medical journal 2021-09, Vol.134 (24), p.2944-2953
Main Authors: Xiong, Tao, Yue, Yan, Li, Wen-Xing, Choonara, Imti, Qazi, Shamim, Chen, Hong-Ju, Tang, Jun, Shi, Jing, Wang, Hua, Zeng, Li-Nan, Xia, Bin, Qiao, Li-Na, Qu, Yi, Mu, De-Zhi
Format: Article
Language:English
Subjects:
Anti-Bacterial Agents - therapeutic use
Antibiotics
Azithromycin - therapeutic use
Bias
Children & youth
Drug dosages
Humans
Infant
Infections
Infectious diseases
Mass Drug Administration
Prevalence
Public health
Systematic Review
Trachoma - drug therapy
Trachoma - epidemiology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c5476-a59efb7315207c54bae6ea054c53c5cb2355361e7b4b39fc7276908af59368cb3
cites cdi_FETCH-LOGICAL-c5476-a59efb7315207c54bae6ea054c53c5cb2355361e7b4b39fc7276908af59368cb3
container_end_page 2953
container_issue 24
container_start_page 2944
container_title Chinese medical journal
container_volume 134
creator Xiong, Tao
Yue, Yan
Li, Wen-Xing
Choonara, Imti
Qazi, Shamim
Chen, Hong-Ju
Tang, Jun
Shi, Jing
Wang, Hua
Zeng, Li-Nan
Xia, Bin
Qiao, Li-Na
Qu, Yi
Mu, De-Zhi
description Azithromycin mass drug administration (MDA) is a key part of the strategy for controlling trachoma. This systematic review aimed to comprehensively summarize the present studies of azithromycin MDA on trachoma; provide an overview of the impact of azithromycin MDA on trachoma in different districts; and explore the possible methods to enhance the effectiveness of azithromycin MDA in hyperendemic districts. PubMed, Embase, the Cochrane Central Register of Controlled Trials, Web of Science, and ClinicalTrials.gov were searched up to February 2021 with no language restriction. Studies reporting the effect of azithromycin MDA on trachoma were included. Mathematical modeling studies, animal studies, case reports, and reviews were excluded. The trachomatous inflammation-follicular (TF)
doi_str_mv 10.1097/CM9.0000000000001717
format article
fullrecord <record><control><sourceid>proquest_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_5f001698fa304e368f907cdcac07bbaa</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_5f001698fa304e368f907cdcac07bbaa</doaj_id><sourcerecordid>2583446895</sourcerecordid><originalsourceid>FETCH-LOGICAL-c5476-a59efb7315207c54bae6ea054c53c5cb2355361e7b4b39fc7276908af59368cb3</originalsourceid><addsrcrecordid>eNpdkt9rFDEQxxdRbK3-ByILvviyNb-z8UGQo2qh4oviY5jNTe5y7m5qsnvH-deb82ptGwIZJt_5ZGYyVfWSknNKjH67-GLOyZ1FNdWPqlMmBWukEvRxdUq4Uo0yxpxUz3LeEMKk1OppdcKFUsWkp9WPC-_RTWGLI-ZcR1_D7zCtUxz2Loz1AMW5TPOqhuUQxpCnBFOIY112Md06DvCuhjrv84RDuXJ1wm3A3fPqiYc-44ub86z6_vHi2-Jzc_X10-Xiw1XjpNCqAWnQd5pTyYgurg5QIRApnOROuo5xKbmiqDvRceOdZloZ0oKXhqvWdfysujxylxE29jqFAdLeRgj2ryOmlYVU0urRSl-apEzrgROBJdyb8ubSgSO66wAK6_2RdT13Ay4djqXE_h70_s0Y1nYVt7bVlHDRFsCbG0CKv2bMkx1Cdtj3MGKcs2Wy5UKo1sgiff1AuolzGkurLFOUaSao4kUljiqXYs4J_W0ylNjDFNgyBfbhFJSwV3cLuQ369-3_ubvYT5jyz37eYbJrhH5aH3jMcE4aRhiljBHSHNCK_wF5lr2Q</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2612724163</pqid></control><display><type>article</type><title>Effectiveness of azithromycin mass drug administration on trachoma: a systematic review</title><source>Open Access: PubMed Central</source><source>HEAL-Link subscriptions: Lippincott Williams &amp; Wilkins</source><source>Publicly Available Content Database</source><creator>Xiong, Tao ; Yue, Yan ; Li, Wen-Xing ; Choonara, Imti ; Qazi, Shamim ; Chen, Hong-Ju ; Tang, Jun ; Shi, Jing ; Wang, Hua ; Zeng, Li-Nan ; Xia, Bin ; Qiao, Li-Na ; Qu, Yi ; Mu, De-Zhi</creator><creatorcontrib>Xiong, Tao ; Yue, Yan ; Li, Wen-Xing ; Choonara, Imti ; Qazi, Shamim ; Chen, Hong-Ju ; Tang, Jun ; Shi, Jing ; Wang, Hua ; Zeng, Li-Nan ; Xia, Bin ; Qiao, Li-Na ; Qu, Yi ; Mu, De-Zhi</creatorcontrib><description>Azithromycin mass drug administration (MDA) is a key part of the strategy for controlling trachoma. This systematic review aimed to comprehensively summarize the present studies of azithromycin MDA on trachoma; provide an overview of the impact of azithromycin MDA on trachoma in different districts; and explore the possible methods to enhance the effectiveness of azithromycin MDA in hyperendemic districts. PubMed, Embase, the Cochrane Central Register of Controlled Trials, Web of Science, and ClinicalTrials.gov were searched up to February 2021 with no language restriction. Studies reporting the effect of azithromycin MDA on trachoma were included. Mathematical modeling studies, animal studies, case reports, and reviews were excluded. The trachomatous inflammation-follicular (TF) &lt;5.0% was used to judge the effect of azithromycin MDA on eliminating trachoma as a public health problem. Two researchers independently conducted the selection process and risk of bias assessment. A total of 1543 studies were screened, of which 67 studies including 13 cluster-randomized controlled trials and 54 non-randomized studies were included. The effect of azithromycin MDA on trachoma was closely related to the baseline prevalence in districts. For the districts with baseline prevalence between 5.0% and 9.9%, a single round of MDA achieved a TF &lt;5.0%. For the districts with baseline between 10.0% and 29.9%, annual MDA for 3 to 5 years reduced TF &lt;5.0%. However, for the districts with high level of baseline prevalence (TF &gt;30.0%), especially with baseline TF &gt;50.0%, annual MDA was unable to achieve the TF &lt;5.0% even after 5 to 7 years of treatment. Quarterly MDA is more effective in controlling trachoma in these hyperendemic districts. Azithromycin MDA for controlling trachoma depends on the baseline prevalence. The recommendation by the World Health Organization that annual MDA for 3 to 5 years in the districts with TF baseline &gt;10.0% is not appropriate for all eligible districts.</description><identifier>ISSN: 0366-6999</identifier><identifier>EISSN: 2542-5641</identifier><identifier>DOI: 10.1097/CM9.0000000000001717</identifier><identifier>PMID: 34665571</identifier><language>eng</language><publisher>China: Lippincott Williams &amp; Wilkins</publisher><subject>Anti-Bacterial Agents - therapeutic use ; Antibiotics ; Azithromycin - therapeutic use ; Bias ; Children &amp; youth ; Drug dosages ; Humans ; Infant ; Infections ; Infectious diseases ; Mass Drug Administration ; Prevalence ; Public health ; Systematic Review ; Trachoma - drug therapy ; Trachoma - epidemiology</subject><ispartof>Chinese medical journal, 2021-09, Vol.134 (24), p.2944-2953</ispartof><rights>Lippincott Williams &amp; Wilkins</rights><rights>Copyright © 2021 The Chinese Medical Association, produced by Wolters Kluwer, Inc. under the CC-BY-NC-ND license.</rights><rights>Copyright © 2021 The Chinese Medical Association, produced by Wolters Kluwer, Inc. under the CC-BY-NC-ND license. This work is published under http://creativecommons.org/licenses/by-nc-nd/4.0 (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>Copyright © 2021 The Chinese Medical Association, produced by Wolters Kluwer, Inc. under the CC-BY-NC-ND license. 2021</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c5476-a59efb7315207c54bae6ea054c53c5cb2355361e7b4b39fc7276908af59368cb3</citedby><cites>FETCH-LOGICAL-c5476-a59efb7315207c54bae6ea054c53c5cb2355361e7b4b39fc7276908af59368cb3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8710348/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/2612724163?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,25753,27924,27925,37012,37013,44590,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/34665571$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Xiong, Tao</creatorcontrib><creatorcontrib>Yue, Yan</creatorcontrib><creatorcontrib>Li, Wen-Xing</creatorcontrib><creatorcontrib>Choonara, Imti</creatorcontrib><creatorcontrib>Qazi, Shamim</creatorcontrib><creatorcontrib>Chen, Hong-Ju</creatorcontrib><creatorcontrib>Tang, Jun</creatorcontrib><creatorcontrib>Shi, Jing</creatorcontrib><creatorcontrib>Wang, Hua</creatorcontrib><creatorcontrib>Zeng, Li-Nan</creatorcontrib><creatorcontrib>Xia, Bin</creatorcontrib><creatorcontrib>Qiao, Li-Na</creatorcontrib><creatorcontrib>Qu, Yi</creatorcontrib><creatorcontrib>Mu, De-Zhi</creatorcontrib><title>Effectiveness of azithromycin mass drug administration on trachoma: a systematic review</title><title>Chinese medical journal</title><addtitle>Chin Med J (Engl)</addtitle><description>Azithromycin mass drug administration (MDA) is a key part of the strategy for controlling trachoma. This systematic review aimed to comprehensively summarize the present studies of azithromycin MDA on trachoma; provide an overview of the impact of azithromycin MDA on trachoma in different districts; and explore the possible methods to enhance the effectiveness of azithromycin MDA in hyperendemic districts. PubMed, Embase, the Cochrane Central Register of Controlled Trials, Web of Science, and ClinicalTrials.gov were searched up to February 2021 with no language restriction. Studies reporting the effect of azithromycin MDA on trachoma were included. Mathematical modeling studies, animal studies, case reports, and reviews were excluded. The trachomatous inflammation-follicular (TF) &lt;5.0% was used to judge the effect of azithromycin MDA on eliminating trachoma as a public health problem. Two researchers independently conducted the selection process and risk of bias assessment. A total of 1543 studies were screened, of which 67 studies including 13 cluster-randomized controlled trials and 54 non-randomized studies were included. The effect of azithromycin MDA on trachoma was closely related to the baseline prevalence in districts. For the districts with baseline prevalence between 5.0% and 9.9%, a single round of MDA achieved a TF &lt;5.0%. For the districts with baseline between 10.0% and 29.9%, annual MDA for 3 to 5 years reduced TF &lt;5.0%. However, for the districts with high level of baseline prevalence (TF &gt;30.0%), especially with baseline TF &gt;50.0%, annual MDA was unable to achieve the TF &lt;5.0% even after 5 to 7 years of treatment. Quarterly MDA is more effective in controlling trachoma in these hyperendemic districts. Azithromycin MDA for controlling trachoma depends on the baseline prevalence. The recommendation by the World Health Organization that annual MDA for 3 to 5 years in the districts with TF baseline &gt;10.0% is not appropriate for all eligible districts.</description><subject>Anti-Bacterial Agents - therapeutic use</subject><subject>Antibiotics</subject><subject>Azithromycin - therapeutic use</subject><subject>Bias</subject><subject>Children &amp; youth</subject><subject>Drug dosages</subject><subject>Humans</subject><subject>Infant</subject><subject>Infections</subject><subject>Infectious diseases</subject><subject>Mass Drug Administration</subject><subject>Prevalence</subject><subject>Public health</subject><subject>Systematic Review</subject><subject>Trachoma - drug therapy</subject><subject>Trachoma - epidemiology</subject><issn>0366-6999</issn><issn>2542-5641</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>PIMPY</sourceid><sourceid>DOA</sourceid><recordid>eNpdkt9rFDEQxxdRbK3-ByILvviyNb-z8UGQo2qh4oviY5jNTe5y7m5qsnvH-deb82ptGwIZJt_5ZGYyVfWSknNKjH67-GLOyZ1FNdWPqlMmBWukEvRxdUq4Uo0yxpxUz3LeEMKk1OppdcKFUsWkp9WPC-_RTWGLI-ZcR1_D7zCtUxz2Loz1AMW5TPOqhuUQxpCnBFOIY112Md06DvCuhjrv84RDuXJ1wm3A3fPqiYc-44ub86z6_vHi2-Jzc_X10-Xiw1XjpNCqAWnQd5pTyYgurg5QIRApnOROuo5xKbmiqDvRceOdZloZ0oKXhqvWdfysujxylxE29jqFAdLeRgj2ryOmlYVU0urRSl-apEzrgROBJdyb8ubSgSO66wAK6_2RdT13Ay4djqXE_h70_s0Y1nYVt7bVlHDRFsCbG0CKv2bMkx1Cdtj3MGKcs2Wy5UKo1sgiff1AuolzGkurLFOUaSao4kUljiqXYs4J_W0ylNjDFNgyBfbhFJSwV3cLuQ369-3_ubvYT5jyz37eYbJrhH5aH3jMcE4aRhiljBHSHNCK_wF5lr2Q</recordid><startdate>20210916</startdate><enddate>20210916</enddate><creator>Xiong, Tao</creator><creator>Yue, Yan</creator><creator>Li, Wen-Xing</creator><creator>Choonara, Imti</creator><creator>Qazi, Shamim</creator><creator>Chen, Hong-Ju</creator><creator>Tang, Jun</creator><creator>Shi, Jing</creator><creator>Wang, Hua</creator><creator>Zeng, Li-Nan</creator><creator>Xia, Bin</creator><creator>Qiao, Li-Na</creator><creator>Qu, Yi</creator><creator>Mu, De-Zhi</creator><general>Lippincott Williams &amp; Wilkins</general><general>Lippincott Williams &amp; Wilkins Ovid Technologies</general><general>Wolters Kluwer</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope></search><sort><creationdate>20210916</creationdate><title>Effectiveness of azithromycin mass drug administration on trachoma: a systematic review</title><author>Xiong, Tao ; Yue, Yan ; Li, Wen-Xing ; Choonara, Imti ; Qazi, Shamim ; Chen, Hong-Ju ; Tang, Jun ; Shi, Jing ; Wang, Hua ; Zeng, Li-Nan ; Xia, Bin ; Qiao, Li-Na ; Qu, Yi ; Mu, De-Zhi</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c5476-a59efb7315207c54bae6ea054c53c5cb2355361e7b4b39fc7276908af59368cb3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Anti-Bacterial Agents - therapeutic use</topic><topic>Antibiotics</topic><topic>Azithromycin - therapeutic use</topic><topic>Bias</topic><topic>Children &amp; youth</topic><topic>Drug dosages</topic><topic>Humans</topic><topic>Infant</topic><topic>Infections</topic><topic>Infectious diseases</topic><topic>Mass Drug Administration</topic><topic>Prevalence</topic><topic>Public health</topic><topic>Systematic Review</topic><topic>Trachoma - drug therapy</topic><topic>Trachoma - epidemiology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Xiong, Tao</creatorcontrib><creatorcontrib>Yue, Yan</creatorcontrib><creatorcontrib>Li, Wen-Xing</creatorcontrib><creatorcontrib>Choonara, Imti</creatorcontrib><creatorcontrib>Qazi, Shamim</creatorcontrib><creatorcontrib>Chen, Hong-Ju</creatorcontrib><creatorcontrib>Tang, Jun</creatorcontrib><creatorcontrib>Shi, Jing</creatorcontrib><creatorcontrib>Wang, Hua</creatorcontrib><creatorcontrib>Zeng, Li-Nan</creatorcontrib><creatorcontrib>Xia, Bin</creatorcontrib><creatorcontrib>Qiao, Li-Na</creatorcontrib><creatorcontrib>Qu, Yi</creatorcontrib><creatorcontrib>Mu, De-Zhi</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health &amp; Medical Collection (Proquest)</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>PML(ProQuest Medical Library)</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>Chinese medical journal</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Xiong, Tao</au><au>Yue, Yan</au><au>Li, Wen-Xing</au><au>Choonara, Imti</au><au>Qazi, Shamim</au><au>Chen, Hong-Ju</au><au>Tang, Jun</au><au>Shi, Jing</au><au>Wang, Hua</au><au>Zeng, Li-Nan</au><au>Xia, Bin</au><au>Qiao, Li-Na</au><au>Qu, Yi</au><au>Mu, De-Zhi</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Effectiveness of azithromycin mass drug administration on trachoma: a systematic review</atitle><jtitle>Chinese medical journal</jtitle><addtitle>Chin Med J (Engl)</addtitle><date>2021-09-16</date><risdate>2021</risdate><volume>134</volume><issue>24</issue><spage>2944</spage><epage>2953</epage><pages>2944-2953</pages><issn>0366-6999</issn><eissn>2542-5641</eissn><abstract>Azithromycin mass drug administration (MDA) is a key part of the strategy for controlling trachoma. This systematic review aimed to comprehensively summarize the present studies of azithromycin MDA on trachoma; provide an overview of the impact of azithromycin MDA on trachoma in different districts; and explore the possible methods to enhance the effectiveness of azithromycin MDA in hyperendemic districts. PubMed, Embase, the Cochrane Central Register of Controlled Trials, Web of Science, and ClinicalTrials.gov were searched up to February 2021 with no language restriction. Studies reporting the effect of azithromycin MDA on trachoma were included. Mathematical modeling studies, animal studies, case reports, and reviews were excluded. The trachomatous inflammation-follicular (TF) &lt;5.0% was used to judge the effect of azithromycin MDA on eliminating trachoma as a public health problem. Two researchers independently conducted the selection process and risk of bias assessment. A total of 1543 studies were screened, of which 67 studies including 13 cluster-randomized controlled trials and 54 non-randomized studies were included. The effect of azithromycin MDA on trachoma was closely related to the baseline prevalence in districts. For the districts with baseline prevalence between 5.0% and 9.9%, a single round of MDA achieved a TF &lt;5.0%. For the districts with baseline between 10.0% and 29.9%, annual MDA for 3 to 5 years reduced TF &lt;5.0%. However, for the districts with high level of baseline prevalence (TF &gt;30.0%), especially with baseline TF &gt;50.0%, annual MDA was unable to achieve the TF &lt;5.0% even after 5 to 7 years of treatment. Quarterly MDA is more effective in controlling trachoma in these hyperendemic districts. Azithromycin MDA for controlling trachoma depends on the baseline prevalence. The recommendation by the World Health Organization that annual MDA for 3 to 5 years in the districts with TF baseline &gt;10.0% is not appropriate for all eligible districts.</abstract><cop>China</cop><pub>Lippincott Williams &amp; Wilkins</pub><pmid>34665571</pmid><doi>10.1097/CM9.0000000000001717</doi><tpages>10</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0366-6999
ispartof Chinese medical journal, 2021-09, Vol.134 (24), p.2944-2953
issn 0366-6999
2542-5641
language eng
recordid cdi_doaj_primary_oai_doaj_org_article_5f001698fa304e368f907cdcac07bbaa
source Open Access: PubMed Central; HEAL-Link subscriptions: Lippincott Williams & Wilkins; Publicly Available Content Database
subjects Anti-Bacterial Agents - therapeutic use
Antibiotics
Azithromycin - therapeutic use
Bias
Children & youth
Drug dosages
Humans
Infant
Infections
Infectious diseases
Mass Drug Administration
Prevalence
Public health
Systematic Review
Trachoma - drug therapy
Trachoma - epidemiology
title Effectiveness of azithromycin mass drug administration on trachoma: a systematic review
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-26T22%3A09%3A15IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Effectiveness%20of%20azithromycin%20mass%20drug%20administration%20on%20trachoma:%20a%20systematic%20review&rft.jtitle=Chinese%20medical%20journal&rft.au=Xiong,%20Tao&rft.date=2021-09-16&rft.volume=134&rft.issue=24&rft.spage=2944&rft.epage=2953&rft.pages=2944-2953&rft.issn=0366-6999&rft.eissn=2542-5641&rft_id=info:doi/10.1097/CM9.0000000000001717&rft_dat=%3Cproquest_doaj_%3E2583446895%3C/proquest_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c5476-a59efb7315207c54bae6ea054c53c5cb2355361e7b4b39fc7276908af59368cb3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2612724163&rft_id=info:pmid/34665571&rfr_iscdi=true